Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz

Patent Law

: IPBiz

CIRM's position on bio-similars

By Lawrence B. Ebert, Esq.

Senator Feinstein included a copy of a letter from CIRM to Feinstein within her letter to Senators Kennedy and Dodd on legislation on bio-similars (generic biologics in Affordable Choices Act). Within the CIRM letter, there is a portion attacking a report of the FTC which portion includes the words:

According to the FTC, corporations typically fund incremental innovation to support pre-existing core business.

That, of course, could be used to suggest why the experience of David Kappos at IBM might not be the ideal choice of background for USPTO director.

CIRM did not deny the truth of the statement by the FTC, but noted it did not apply to stem cell companies. That would lead to another argument against Kappos.

CIRM employs the Podesta lobbying group.

Full post as published by IPBiz on August 05, 2009 (boomark / email).